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FRONTIERS IN PRECISION MEDICINE II:
CANCER, BIG DATA AND THE PUBLIC
December 1-2, 2016
Conference Proceedings
Emily Coonrod, Jorge L. Contreras, Willard Dere, Jeffrey Botkin, Leslie P.
Francis, James Tabery1
In a December 2016 interview with Bloomberg BNA, Dr. Francis Collins,
Director of the U.S. National Institutes of Health, predicted that precision
medicine “is going to change everything about how we understand health and
disease.”2 The massive Precision Medicine Initiative (PMI), now re-named the
“All of Us” Research Program, plans to study a cohort of more than one million
Americans. Its hope is to expand our understanding of heredity and disease and
revolutionize the treatment of disease and the improvement of human health.
According to the White House, precision medicine is “health care tailored
for you.”3 At its most fundamental level, precision medicine seeks to optimize
treatments based on individual physiological characteristics, such as the ability to
metabolize certain compounds or to respond to one or another set of drugs
based on individual differences in genes, environments, and lifestyles.
Precision medicine is being developed today within a complex landscape
of medicine, science, public policy, law, and ethics. In December 2016, the
University of Utah School of Medicine, Huntsman Cancer Institute and S.J.
Quinney College of Law held their second annual symposium on current issues
in precision medicine. This year, the focus of symposium was on cancer and how
precision medicine can enlist “big data” to combat what has been termed “the
emperor of all maladies” -- cancer.4
This two-day event convened national experts in genetics, medicine,
bioinformatics, intellectual property, health communications and bioethics to
discuss and debate many of the pressing questions raised by precision medicine
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as it relates to cancer research. 5 The key arguments, conclusions and
unresolved issues that emerged from the symposium are summarized in these
proceedings. Speakers and participants are referred to by name in the text, with
the full conference agenda and speaker names and affiliations in the Appendix.
1. Tackling Cancer With Precision Data
a. The Science Of Precision Oncology
The first session of the Frontiers in Precision Medicine II: Cancer, Big
Data and the Public conference hosted by the University of Utah explored issues
facing successful clinical implementation of precision medicine in oncology. Ana
Maria Lopez introduced this session and kicked off the symposium. She
described the elements that will ensure the success of precision medicine
including a team science approach, data sharing policies, insurance coverage,
and inclusive patient engagement. She stressed the importance of patient
engagement and warned that without it, clinical outcomes for diverse
communities may worsen and health disparities may grow. When an inclusive
approach to precision medicine is taken, these concepts can be applied to public
health to stratify risk at the population level and improve prevention and
treatment with targeted strategies that will ultimately lead to disease prevention,
health promotion, and health inequity reduction.
Following Dr. Lopez’s introduction, Kathleen Cooney provided an overview
of precision oncology and discussed specific approaches to its implementation in
clinical care. Dr. Cooney noted that cancer is a common disease with 1.7 million
newly diagnosed cases per year and is responsible for 600,000 deaths per year
in the United States. In addition, the cost of cancer care is predicted to balloon to
$170 billion per year by 2020 due to an increasingly aging population and the
increasing costs of new cancer therapies. The evolving recognition of cancer as
a genetic disease that can be caused by both germline mutations (mutations in
every cell of the body that can be passed on to one’s children) and somatic
mutations (mutations that develop in certain cells in the body that are not passed
on to one’s children) has made the practice of precision oncology a reality. The
practice of precision oncology is reliant on new technology that rapidly generates
sequencing data on all genes in tumor and non-tumor cells from cancer patients.
Dr. Cooney pointed out that early successes with therapies targeted to specific
mutations serve as a proof of principle that this approach works, although
responses are not always sustained. In addition, these therapies are expensive,
5
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have unique side effects, and can contribute to the development of drug resistant
tumors. These discoveries demonstrate the significant impact that the
implementation of precision oncology can have on both individual patients and
public health, as discussed earlier by Dr. Lopez.
Although targeted therapies can be successful, they have uncovered new
challenges to patient care. Without a systematic approach to identifying
actionable mutations, many may be unable to access new therapies. The
Princess Margaret IMPACT/COMPACT trial, a large study with 1,640
participants, revealed that only 15% of patients in the study were ultimately
enrolled in clinical trials and only 5% were enrolled in clinical trials for a drug that
was targeted to their specific genetic diagnosis.6 This study made clear that
routinely matching therapies to actionable mutations is another hurdle to
overcome in the implementation of precision oncology in the clinical setting.
Dr. Cooney described a multi-disciplinary, team approach to precision
oncology, the MI-ONCOSEQ (Michigan Oncology Sequencing Center). In this
model, the patient first meets with both a medical oncologist and a genetic
counselor and provides informed consent. A biopsy of the tumor is then obtained
along with a saliva or blood sample. DNA is extracted from the biological
specimens and sequenced. Genomic data are analyzed and a Precision
Medicine Tumor Board meets to determine if results can inform the patient’s
clinical treatment and if there are additional findings that will impact the patient’s
health. The Precision Medicine Tumor Board is composed of experts in clinical
oncology, genomics, bioinformatics, pathology, clinical genetics, and bioethics. A
patient advocate serves on this Board to ensure inclusion of the patient
perspective in the decision-making process. Results are returned to the patient
by both the genetic counselor and the medical oncologist. Dr. Cooney then
illustrated success stories from the MI-ONCOSEQ project describing patients
with medically actionable mutations that responded extremely well to the
targeted, molecularly matched treatment recommended by the Tumor Board. In
summary, although the genetic cause of cancer can now be identified, doing so
requires a multidisciplinary, team based approach.
Dr. Scott Tomlins closed the session with a presentation exploring the
“hype versus reality” of precision oncology and reinforced some of Dr. Cooney’s
comments. Dr. Tomlins noted that identifying medically actionable mutations in
cancer patients is not sufficient to drive clinical choices for cancer care. What
really matters when moving precision oncology to the clinic is determining how
many patients are enrolled in clinical trials based on their sequencing results and
how many of these patients have a favorable response to therapy. Dr. Tomlins
used the same example mentioned by Dr. Cooney from the IMPACT/COMPACT
6
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trial7 to illustrate that not every patient is benefitting from sequencing and that the
field needs to study further the clinical utility of sequencing for patient care and
clinical outcomes. Some large studies are beginning to tackle this by enrolling
patients at multiple centers around the country and matching patients with a
specific drug based on their genetic results. In this approach, patients are not
treated by the anatomical type of cancer they have (e.g., lung, colon, breast), but
rather by the mutation causing their cancer. Although this approach will get us
closer to understanding patient outcomes, there are still barriers to doing this on
a very large scale. The cost of sequencing a large number of people is still high
and new therapies are approved for treatment of a specific type of cancer rather
than a molecular signature, meaning that pharmaceutical companies will
encounter regulatory barriers to drug approval using this approach. Dr. Tomlins
also pointed out that there are a number of genes known to cause a high
percentage of cancers that have been recalcitrant to therapeutic targeting, such
as TP53, KRAS, MYC, APC, CTNNB1, and PIK3CA. New approaches to drug
development will be necessary to target the genes that are responsible for many
cancer cases. Lastly, Dr. Tomlins predicts that immunotherapy will have the
most impact on clinical outcomes because sequencing allows for the creation of
an antigen specific to the patients’ tumor that will be attacked by their own
immune system. To summarize, Dr. Tomlins urges the field to move beyond
sequencing to understand clinical utility. This requires improving enrollment of
patients into matched clinical trials and systematically measuring outcomes.
b. The Challenges Of Big Data
New and innovative informatics approaches are necessary to unlock the
promise of precision medicine in clinical practice, but working with the large
datasets produced by next generation sequencing poses a number of challenges
being tackled at institutions around the country. Dr. Rakesh Nagarajan described
the convergence of three major innovations that have led to the rapid emergence
of precision medicine. First is the development of the technology to do massively
parallel sequencing with a cost that continues to decrease. Second is a dramatic
increase in medical knowledge-bases enables the interpretation of this
sequencing data to inform clinical practices, such as prescribing targeted drugs
and immunotherapies. Third are advances in information management and
informatics that are bridging the production of sequencing data and medical
knowledge to make precision medicine possible. There remain a number of
barriers to truly conducting precision medicine at scale to sustain the current
exponential growth of DNA sequencing. At a high level, these barriers include
acquisition of the data, data storage solutions, distribution of data on a population
scale, and analysis capabilities.8
7
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Changing the infrastructure of the electronic health record (EHR) is one way
that informatics is being used to address these barriers. The EHR at Washington
University in St Louis School of Medicine alone contains records from ~5.7
million patients with ~40 million encounters, and contains ~89 million text
documents with ~48 million scanned documents. The vast majority of the
genomic data that is produced clinically is found in text documents. This creates
a major informatics problem because it is difficult to electronically extract
information from free text due to inconsistencies in ontologies and vocabulary
standards. Therefore, a test result and its details are not recorded in the EHR in
a way that can be easily extracted and used to treat the patient. An informatics
solution has already been put in place for transferring different types of nongenomic data from disparate sources to the EHR using HL7 messaging to
transfer and store demographic information, laboratory results, and medication
prescribing information in a standardized way. There are now informatics
solutions being developed to achieve the same goal with genomic data. One
example is the HL7 specification Clinical Genomics Object Model to transmit
genomic results as discrete fields.9 However, this standard has not been adopted
by EHR vendors due to low demand. Additional file formats being standardized
for this purpose are CRAM, BAM/SAM, VCF/BCF and HGVS for variant
nomenclature.
Biomedical knowledge-bases are significant resources used by clinical
laboratories to classify variants and determine if variants are clinically actionable.
These knowledge-bases are continuously expanding. However, in order to be
useful, the laboratory and knowledge-base must be using the same human
genome build to annotate variants or have the capability to map variants from
one genome build to another accurately and automatically. There are guidelines
published to organizations such as the American Society of Clinical Oncology
and the FDA, along with medical publications and clinical trial studies, but these
sources are also free text. Oncology Research Sources such as COSMIC,
TCGA, and cBioPortal are available in knowledge-bases to help guide clinical
laboratory interpretations, as are clinical variant databases such as ClinVar,
Emory, ARUP Laboratories, and Invitae. All of these resources aid clinical
interpretation, but pose some of the same challenges described above.
PierianDx has begun to address these problems by creating a network of
thirteen laboratories offering somatic cancer panels clinically. This laboratory
network is conducting clinical tests with 41 different gene panels having an
average panel size of 44 genes. Through this network, PierianDx has been
integrating information from the sources described above to create a curated
knowledge-base for these network laboratories. Genes on panels offered through
9
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this network have been curated with FDA drug label information, National
Comprehensive Cancer Network guidelines, clinically relevant interpretations,
associated clinical trials, and clinical associations. Creating this community
knowledgebase allows PierianDx and its network to aggregate results to better
understand the genetic basis of cancers such as mutation frequency by tumor
type.
This network approach begins to address some of the current informatics
issues, and is already being performed nationally in health care systems such as
the VA’s Precision Oncology Program, which is an integrated database with
clinical, genomic, imaging, and research data processed and analyzed through
Natural Language Processing (NLP). 10 The evolution of these networks will
ultimately create a national learning healthcare system, which integrates genomic
data, prior patient data, and population health data to deliver the best, most
appropriate care possible in the era of genomic medicine. Standards such as
FHIR, a data specification that allows sharing of data formats across
organizations, and the meaningful use-stage 3 program from the Centers for
Medicaid and Medicare Services114 requiring electronic delivery of care records
when patients transition from one hospital organization to another are major
steps toward creating this national network. Current technologies also enable a
disruptive approach to current care delivery by enabling patients to drive their
own healthcare delivery by having access to their individual, comprehensive
electronic medical record and being an active and engaged member of the
healthcare delivery team.12
The second half of the session highlighted systems put in place at the
University of Utah’s Huntsman Cancer Institute (HCI) to deliver precision
medicine. Samir Courdy described the evolution of the informatics infrastructure
at HCI since 1999. Building the capability for delivery of precision medicine
began with a redesign of the IT architecture to enable database technologies and
web capabilities for infrastructure applications. The next phase of pipeline
development from 2002-2006 focused on building the missing links to enable
patient education, research, and delivery of care such as creating a research
subject registry and integration with the University of Utah Hospital’s Enterprise
Data Warehouse (EDW). 2006-2010 was a period of customization, expansion,
and increased efficiencies while building the critical infrastructure for NLP.
Currently, the infrastructure is being expanded to allow for integration of
disparate data sets, collaboration with other institutions, and management of big
data. Like Dr. Nagarajan, Mr. Courdy also pointed out that one of the major
challenges to integration of genomic data into clinical care is our ability to mine
10

http://www.blogs.va.gov/VAntage/22165/va-precision-oncology/. Accessed 6/2/17.
https://www.cms.gov/Regulations-and
Guidance/Legislation/EHRIncentivePrograms/Stage3Medicaid_Require.html. Accessed 6/2/17.
12
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11

Precision Medicine II

Page 7

data from free text. Mr. Courdy predicts that this problem will continue to exist
into the foreseeable future, as clinical laboratories are designed to communicate
results via free text. However, this problem creates opportunities for innovation
and research into NLP and machine learning.
HCI has created a solution for implementing precision medicine termed the
Research Informatics Shared Resource (RISR). This pipeline utilizes both
commercial and non-commercial components to create an information network
that pulls data from the different testing laboratories used by HCI, primarily
Foundation Medicine and the University of Utah’s ARUP Laboratories, into a
research integration engine allowing this data to be deposited into the EHR, the
EDW, and shared with national oncology research networks as appropriate. HCI
is working with testing laboratories to solve the problem of receiving genomic
results in free text format. Foundation Medicine and ARUP Laboratories are now
providing testing data in PDF, BAM, VCF, and/or XML file formats, and HL7
messaging is being used by Foundation Medicine to deposit test results into the
University’s EHR. The HCI team is utilizing commercially available and in-house
developed tools for NLP to turn free text reports into discrete, searchable, and
structured data elements that can be utilized by HCI’s research integration
engine.
Dr. David Nix next discussed his team’s approach to move clinical genomic
samples into a translational research program. There are two types of genomic
data received by HCI, data generated on samples through research, and data
generated on samples through CLIA laboratories from clinical tests. HCI recently
joined the ORIEN network, which aims to leverage multiple data sources from
different institutions to better match patients to targeted treatments. HCI has
implemented the Total Cancer Care protocol, a study whose data is shared with
the ORIEN network. This protocol provides a uniform patient consent form, an
umbrella IRB at each institution to allow data access across institutions, and has
put in place a variety of data sharing mechanisms that allows access to both
clinical and molecular data. Foundation Medicine is the preferred clinical testing
vendor for HCI, because its data is rich and focused on clinical utility, making it
useful for sharing within HCI’s research network. Foundation Medicine’s tests
target clinically actionable genes from tumors in two different gene panel tests
that detect short variants (SNVs and INDELs), copy number variants, and select
gene rearrangements. Importantly, the data are returned to HCI in discrete field
XML clinical reports and unfiltered BAM file formats. These data are then reprocessed before being moved into Mr. Courdy’s pipeline. In order to make
these clinical data useful for a research program, it is imperative to pull out all of
the information from the tests, rather than accessing only the information that is
in the clinical report. Dr. Nix’s team has created a pipeline to re-process the data
from the unfiltered BAM files to normalize the variant calls from different
companies and sources in order to unify the datasets and increase their utility for
research. There are a number of challenges inherent in the re-processing that
are being addressed. First, the output from the re-processing pipeline does not
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always result in the exact same variants called in the clinical laboratory’s reports.
This is due to differences in variant calling and annotation between the two
pipelines. Therefore, it is critical to develop and maintain best practices for the
pipeline, implement as much pipeline automation as possible, and develop NLP
tools to extract data from free text clinical reports. Dr. Nix asked the audience to
consider using drop down menus and ontologies for phenotypic and clinical data
management to help relieve the free text extraction problem.
The pipeline created by HCI utilizes a mixture of commercial and open source
tools, and the team is now focusing on scaling up this pipeline to handle the
deluge of additional data that will be coming to HCI when insurance companies
begin to more routinely reimburse for genetic panel testing in oncology, thus
creating much larger data sets than are currently being managed.
c. Precision Prevention
The next session focused on the topic of precision prevention and featured
discussions on current approaches in the areas of colorectal cancer and lung
cancer. The session was moderated by Dr. Cornelia Ulrich. Dr. Ulrich defined
precision prevention as “tailoring of preventive strategies more precisely, for
example by genetic markers, molecular markers, or overall risk prediction.”
Taking this approach to cancer prevention can maximize the use of resources
and identify specific prevention approaches for groups that will receive the most
benefit. Dr. Ulrich then described her group’s work in exploring the use of aspirin
in colorectal cancer prevention. Aspirin has been shown to reduce the number of
polyps in patients with colorectal cancer, has shown an inverse association with
colorectal cancer and other tumor types in epigenetic studies, and the molecular
pathway affected by aspirin is known. In addition, long term use (10-14 years) of
aspirin at a low dose has been shown to be protective against colorectal
cancer. 13 Although the findings that support the use of aspirin to prevent
colorectal cancer are strong, there are major risks to long term aspirin use,
including GI symptoms and serious bleeding. One way to mitigate these risks is
to tailor the recommendations for long term aspirin use to populations who will
benefit the most while reducing the risk of side effects. Dr. Ulrich’s group has
used pharmacogenomics approaches to uncover a specific genotype that
reduces the risk of colorectal cancer upon regular aspirin use and a genotype
that does not benefit from long term aspirin use. The group is now working on
better understanding the cost effectiveness of using genotype-guided aspirin use
as a primary chemoprevention method in colorectal cancer versus standard
colonoscopy screening. Dr. Ulrich plans to translate these findings into the clinic
to stratify patients at risk for colorectal cancer into groups that will benefit from
13

E. Flossmann, P.M. Rothwell, British Doctors Aspirin Trial & the UK-TIA Aspirin Trial, Effect of
aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and
observational studies, 369 Lancet 1603 (2007).
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aspirin use and those that will not, and to develop a blood test that would allow
people at risk for colorectal cancer and their clinicians to make informed
decisions on whether the benefits of long term aspirin use outweigh its risks.
Next, Dr. Ulrike Peters discussed her group’s efforts to personalize risk
prediction for colorectal cancer. Colorectal cancer is the 3rd leading cause of
cancer-related deaths in the US, and, although very effective screening tools
already exist, approximately one-third of the eligible US population has not
received this screening. In fact, because current guidelines are only based on
age and family history, rates of colorectal cancer are on the rise in populations
that do not meet screening criteria. The goal of Dr. Peters’ group is to create a
comprehensive risk prediction model to stratify people in high risk groups for both
screening and intervention. To realize this goal, Dr. Peters utilizes the large
datasets available through the Genetics and Epidemiology of Colorectal Cancer
Consortium (GECCO). GECCO is a consortium of investigators from multiple
institutions that aggregates data from studies. GECCO allows Dr. Peters’ group
to use genetic information coupled with epidemiological and environmental
information from these studies to innovate new statistical methods for risk
prediction. The risk prediction model being developed takes into consideration
the following variables: age, family history of colorectal cancer, sex, a genetic risk
score, and an environmental risk score while adjusting for endoscopy. Applying
this model to a study cohort of ~8,000 cases and ~9,000 controls showed that
incorporation of the genetic and environmental risk scores increases their ability
to accurately predict colorectal cancer risk. Dr. Peters is also using this risk
prediction model to inform the age at which an individual would benefit from
screening, thus predicting the appropriate age based on the individual’s risk to
start receiving the life-saving colorectal cancer screening. The next step in this
work is to bring personalized screening into public health practice and clinical
care. To do so, the risk prediction modeling will need to be further tested in a
community based setting and used to predict earlier stages of disease. In
addition, the model needs to be subjected to validation and cost effectiveness
studies, culminating in a clinical trial to show its utility in colorectal cancer
prevention.
Dr. Marc Lenburg then described his work in the area of precision lung cancer
prevention. Lung cancer is the second leading cancer diagnosis and the leading
cause of cancer death in the US. However, early detection of lung cancer
through screening is known to reduce mortality of this disease.14,15 Screening for
lung cancer by imaging is the most common technique, but this approach leads
to high rates of false positives, and only 4% of individuals showing abnormal lung
masses by imaging actually have lung cancer. A definitive lung cancer diagnosis
14
15

C.F. Mountain, A new international staging system for lung cancer. 89 Chest 225S (1986).

National Lung Screening Trial Research, et al. Reduced lung-cancer mortality with low-dose
computed tomographic screening. 365 N. Engl. J. Med 395 (2011).
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requires the examination of tissue pathology, which is obtained through an
invasive diagnostic procedure such as bronchoscopy, needle biopsy, or surgical
resection. Therefore, precision prevention of this disease requires the integration
of molecular information to guide the diagnostic workup and prevent unnecessary
invasive procedures.
The group’s early work in this area utilized expression profiling of genes
expressed in bronchial tissue to develop a predictive biomarker. The team
analyzed gene expression profiles in samples from normal appearing cells
collected during bronchoscopy and identified a panel of 80 genes showing
different patterns of gene expression from normal vs. diseased cells. 16 This
approach was validated in a clinical trial 17,18 and is now utilized clinically to
differentiate individuals who only need further monitoring from those who require
more invasive diagnostic procedures to definitively identify whether a mass is
cancer or not. Dr. Lenburg and his team are now moving toward identifying a
tissue source that is even less invasive and costly than collecting bronchial
tissue. Their studies have focused on cells from nasal tissue collected through a
nasal swab based on the theory that if the entire respiratory tract is affected by
lung cancer disease processes, then these processes may be detectable
molecularly in a tissue type that is more accessible than bronchial tissue. Current
work has identified a molecular signature and has shown that adding the
molecular information on top of the clinical information leads to improvements in
diagnostic sensitivity.19 Taken together, this work is leading to less invasive,
more cost-effective mechanisms to detect lung cancer early and accurately to
ensure that the people who need treatment are getting it as soon as possible,
and those that do not have lung cancer are not being subjected to costly and
unnecessary procedures.
2. Catalyzing Translational Innovation
Dr. Chris Austin, director of the National Center for Advancing
Translational Sciences at NIH (NCATS) addressed the topic of personalized
medicine from the perspectives of both key national initiatives and a broader
institutional effort at NIH. President Obama’s State of the Union address in 2015
introduced the Precision Medicine Initiative as an important platform by which the
U.S. could more deeply understand variations in individual responses to
16

A. Spira, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with
suspect lung cancer. 13 Nat. Med. 361 (2007).
17
G.A. Silvestri, et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung
Cancer. 373 N. Engl. J. Med. 243 (2015).
18
D.H. Whitney, et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective
study of patients undergoing diagnostic bronchoscopy. 8 BMC Med Genomics18 (2015).
19
J.F. Perez-Rogers, et al. Shared Gene Expression Alterations in Nasal and Bronchial
Epithelium for Lung Cancer Detection. 109 Jnci-J Natl Cancer I (2017).
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therapeutic interventions; gain health insights through discoveries made possible
by genetic and genomic advances; help address deficiencies in studying underrepresented populations; and use modern technologies such as mobile sensors
to better monitor health status. The original design--to enroll a cohort of one
million individuals who would be followed longitudinally over a number of
decades—is now being realized as the “All of Us” study.20 In addition to the data
and information derived from this cohort, there are important goals to improve the
culture and environment of clinical research in the US by improving the quality of
informed consent; better data sharing; and more assiduous response to
participant inquiries and return of clinical data results. One year later, an
initiative, the “Cancer Moonshot”, to accelerate the progress of discovery in
oncology was announced. Its goals are similar, namely to accelerate discovery
and improve individual patient care through either better targeted therapies or
stratification to enhance preventive testing. Key facets of the initiative include the
importance of direct patient involvement; team science and national networks in
a variety of disciplines including immunotherapy, overcoming cancer resistance,
and systematic approach to childhood cancers.
In many ways, these two initiatives are an extension of the NIH focus on
improving translational research—namely getting basic discoveries to the public--and is the remit of NCATS. NCATS has a two-fold goal: making fundamental
discoveries to treat diseases, like its efforts in rare diseases that afflict
approximately 25 million Americans, and improving the science of translation,
namely applying the scientific method of evaluating processes and scientific
platforms to improve clinical research. Dr. Austin identified the broader societal
problem that NCATS attempts to address as follows: As a biomedical community,
we are making major scientific advances at the discovery bench, and due to
advances in technology, are poised to make even more discoveries directed to
understanding the genetic basis for thousands of rare diseases. Unfortunately,
our antiquated processes to translate these basic discoveries to improvements in
clinical care greatly delay the possibilities of enhancing the impact of discoveries
on broader public health. Thus, Dr. Austin has focused NCATS on improving
both the processes and culture of translational research, with full awareness that
quantum advances are more important than small incremental improvements.
Two such process improvements and innovations include: (1) better utilization of
available libraries of small molecules and information about their pharmacology
profiles to identify potential treatments for rare diseases; and (2) developing tools
better to predict the potential toxicities of potential new therapies.
The CTSA (Clinical and Translational Science Award) program is one of
the centerpieces of NCATS’s efforts, and supports translational research efforts
in approximately 60 academic medical centers. The program seeks to help
improve the culture of translational research by rewarding team science and
collaboration, in addition to supporting other vital goals such as training the next
20

https://allofus.nih.gov/. Accessed 11/7/2017
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generation of biomedical scientists, and emphasizing the importance of deep
community engagement and patient-centered research. One area of immediate
priority is to establish an effective consortium of the CTSA centers (called the
Trial Innovation Network) which can readily participate in multi-center clinical
trials by making the trial planning and initiation processes more efficient through
various measures such as single IRB approval and improved contracting.21
3. The Public And Precision Medicine
a. Recruiting Large Research Cohorts
The ambitious plan of the “All of Us” Research Program is to recruit 1,000,000
or more American volunteers who will provide researchers with access to their
genetic information, their environmental exposures and activities, and their
electronic medical records, all with the aim of understanding how genetic
predispositions, environmental exposures, and lifestyle choices contribute to
health and disease. This program has been praised for its ambitious size and
scope, its tremendous clinical promise, and its daunting set of scientific,
technological, and ethical-legal challenges.
The combination of excitement and trepidation surrounding the All of Us
Research Program might give some the impression that it is the first effort to
create a large, longitudinal research cohort designed to investigate genetic and
environmental impacts on health. In fact, however, a number of regional,
national, and international programs have been created in the last 15 years with
precisely that design and purpose. As the United States embarks on the next
national cohort, there are valuable lessons to be learned from others who have
already gone down that path. This session sought to gain insights from two
researchers who have been intimately involved with efforts in the United States
(one public, one private) to create large, longitudinal research cohorts. Laurence
Meyer discussed the Million Veterans Program that is housed in the Veterans
Administration (VA). Catherine Schaefer described the Research Program on
Genes, Environment and Health run by Kaiser Permanente Northern California
(KPNC). Challenges, foci, and lessons common to both programs were
particularly insightful.
The Million Veterans Program was conceived over a decade ago when
researchers at the VA realized that they had access to a tremendous resource in
the millions of veterans receiving healthcare through the VA medical system. The
VA developed one of the first electronic medical record systems in the world, and
was thus in a strong position to link genetic/environmental/lifestyle information
about their patients with the electronic medical records of those patients which go
back decades. The Research Program on Genes, Environment, and Health was
developed by geneticists and epidemiologists at KPNC in the early-2000s. Like
21
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the researchers at the VA, the KPNC researchers realized that the 3.3 million
members receiving their healthcare through the health delivery system offered a
remarkable potential data set for investigators. Both programs have already
enrolled several hundred thousand participants, and both have been utilized for a
variety of research projects (e.g. a genome-wide association study of
schizophrenia by the VA, and a genome-wide association study of bipolar
disorder by KPNC).
There are striking similarities regarding challenges, foci, and lessons faced by
these two large, longitudinal cohort programs:
Underrepresentation of Young Adults: Both programs struggled to enroll
younger participants (i.e. ages 18-39). The population of the cohorts both skewed
older than the U.S. population. The reasons for lower enrollment among younger
individuals was a topic of speculation—perhaps younger people are more
busy/distracted and so less likely to enroll. Regardless, the underrepresentation
among younger participants is a potential concern for cohort designers and
researchers. If researchers are interested in investigating conditions with earlyadult onset, then it will be important to ensure there are sufficient representatives
from that group to support that research.
Data Management: Both programs encountered significant challenges
associated with managing the data from the cohorts (see also the discussion in
Part I.b, above). Some of these challenges arose from trying to take the
information in electronic medical records, which are designed primarily for the
care of patients, and translating/distilling that into standardized information that
can be quantified and tracked for research purposes. Other challenges arose
from the sheer quantity of data. A single participant can create dozens of data
points from a single questionnaire. When that information is combined with an
electronic medical record, the number of data points jumps to the thousands.
Finally, when genetic information about that participant is figured in, it can
become millions of data points. And that’s just for one participant. When that is
multiplied by the several hundred thousand or million participants in the entire
cohort, the amount of data becomes logistically and technologically daunting.
The VA found this challenge so severe that it had to team up with the
Department of Energy in order to access the computing power necessary to
handle the data. That resource, of course, will not be available to all research
cohorts.
Genetic Focus: Both cohort programs professed an interest in supporting
research on the genetic, environmental, and lifestyle contributions to health and
illness. And yet, the design and performance of both programs indicated a
stronger genetic focus. When giving examples of research supported by the
programs, for example, both Meyer and Schaefer discussed genome-wide
association studies. To be clear: this is not to suggest that the researchers
themselves have a genetic bias. Rather, it is most likely a result of the fact that
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genetic information is much easier to get and analyze than
environmental/lifestyle information. A simple blood or saliva sample can provide
material for producing an individual’s entire human genome. Information about
that same person’s environment and their lifestyle, on the other hand, is much
more difficult to acquire and assess. The cohort programs at the VA and KPNC
both relied in part on questionnaires/surveys administered to their participants to
gather information about lifestyle, but those methods are notoriously unreliable.
Getting objective data about environmental exposures and lifestyle decisions
(with things like wearable monitors, in-home monitoring devices, and geocoded
databases that link participants’ locations with information about environmental
factors in those areas) is more difficult and more expensive. Until measuring the
environment in a reliable way becomes easier and cheaper, these large,
longitudinal research cohorts will continue to produce more information about
genetic contributions to health/disease than environmental/lifestyle contributions
to those same conditions.
Early Community Involvement: Both Meyer and Schaefer emphasized the
importance of getting input from potential participants at the very earliest stages
of cohort creation. The first step in the Million Veterans Program was to ask
veterans affiliated with the VA what they would want the cohort to look like.
Similarly, the program at KPNC created a community advisory board early on in
order to get its advice. Formally implementing this community-input step early is
important because it gives potential participants the opportunity to shape the
cohort program from its inception—to contribute to decisions about what sorts of
research questions the cohort can be designed to answer, what sorts of
motivations make participating attractive, and what sorts of concerns about
participation disincline someone from enrolling.
The differences between the Million Veterans Program at the VA and the
Research Program on Genes, Environment, and Health at KPNC are quite
striking. One is a federal program made up entirely of veterans. The other is a
private program made up entirely of patients/members affiliated with a national
health care delivery system. And yet, both programs encountered similar
challenges (of underrepresented young adults, of data management), produced
similar research results (focused mainly on genetics), and offered similar lessons
(about the importance of involving the community of potential participants early in
the decision-making process). The fact that these similarities occurred despite
the differences in the programs suggests that they are general features that any
large, longitudinal research cohort can face. As the United States embarks on a
new, national cohort—the Precision Medicine Initiative’s All of Us Research
Program—insights from the large, longitudinal cohorts at the VA and KPNC are
likely to prove invaluable.
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b. Engaging The Public In The Program

This session addressed prevalent challenges shared by both the public and
professionals with the communication and interpretation of genetic information
and the informed consent process. Dr. Kimberly Kaphingst emphasized the
prevalence of low health literacy in the general population in the US, noting
particular challenges for minority populations, older individuals, and individuals
with lower educational attainment. For example, data suggest that almost half of
individuals with less than high school or some high school education have a
below basic level of health literacy. The implication is that professional efforts to
communicate complex information to patients must be sensitive to the low levels
of background health literacy that are common in the population. Dr. Kaphingst
also highlighted the difficulties and current inadequacies in obtaining informed
consent for research such as for biobank participation. The average reading
level of the US population is at the 8 – 9th grade level yet consent forms are often
written at a college reading level. The presentation addressed a number of
efforts documented in the literature to improve the content and process of
informed consent. These include communication strategies such as simplified
language, clear organization, descriptive headings, illustrations, and new formats
such as videos. Further, she emphasized need to think beyond the form to
consider enhanced processes involving better training for professionals, more
extended dialogue with patients or research participants, and measures to
assess comprehension. Dr. Kaphingst suggested that there will be no easy
solutions to these challenges but work along a number of avenues to use and
assess better communication strategies will be valuable.
Dr. Angela Fagerlin next addressed a set of challenges in the flow of genetic
information between the laboratory, the health professional, and the patient. A
particular problem in the current state of genetic knowledge is our inability to
provide clear interpretations of many genetic variants identified through testing.
A second set of issues arises from the limited knowledge and experience of
many health care professionals with respect to ordering and interpreting genetic
tests. Data suggest that providers themselves recognize their limits in this
respect and have a low level of confidence in their abilities. Individuals who
obtain genetic information through DTC sources often choose not to share these
results with their physicians because they lack confidence in the ability of their
physician to interpret the information. Several measures have been assessed to
enhance communication of risk-related results between physicians and patients
including different types of graphic presentations. Data indicate that these
measures can impact interpretations of risk. Dr. Fagerlin also addressed public
attitudes about several significant ethical issues in genetic testing, including the
appropriate disclosure of medically actionable results, testing children for adult
onset conditions, and the disclosure of carrier status. Data suggest that lay
individuals will change their opinions to conform more closely with current
professional standards when they are provided information about the ethical
concerns in these domains. This session emphasized the significant challenges
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and barriers to precision medicine arising from the background knowledge of
both professionals and the public and the need for more effective communication
strategies to deal with this complex information.
c. The Ethics of Access and Precision Medicine
The million lives cohort, as planned for the cancer moonshot and the
precision medicine initiative more generally, raises significant issues of justice.
These issues will include recruitment of cohort members, informed consent by
cohort members, participation of cohort members in decisions about data
collection and use, data sharing, communication of findings based on cohort
data, and the ultimate availability of benefits from research discoveries.
Panelists Jessica Roberts and Dr. Maya Sabatello discussed several of these
important issues.
Professor Roberts’s presentation considered downstream and upstream
access issues. Downstream access issues, such as who will have access to the
benefits of the precision medicine initiative are surely important. Benefits such
as individualized forms of cancer treatment can be expected to be very costly.
But Roberts also emphasized the importance of considering upstream barriers to
access. Such barriers might be built into the rules, algorithms, and reference
databases that make up the precision medicine initiative, Prof. Roberts said. If
the information that is collected from participants in the million lives cohort
includes genetic information and clinical information but leaves aside housing,
community safety, employment status, environmental exposures, immigration
status, or available services, it may focus myopically in medical information and
ignore potentially critical roles of the social determinants of health. If certain
groups are underrepresented in the research, results pertaining to them may be
less accurate as well.
The precision medicine initiative is a very expensive enterprise, Roberts
emphasized. It may consume a great deal of research resources and is, itself a
“resource allocation” decision. As such, it is especially important to scrutinize
diseases to be studied, research questions to be asked, and who is more likely to
benefit from the perspective of justice. Prof. Roberts also raised the concern that
historical participation in medical research has been skewed by race and
ethnicity; it will be important that the precision medicine initiative do a better job
of addressing this issue. It will not be easy; African-Americans particularly are
less likely to trust participation in research because of the legacy of Tuskegee
and the more recent telling of the story of Henrietta Lacks.22
Prof. Roberts’ takeaways to the audience were first, that access issues in
precision medicine reach far beyond who has the benefit of using the end
product, to the relative benefits and accuracy of the research for affected
22

Rebecca Skloot, The Immortal Life of Henrietta Lacks (2010).
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populations, and second, that the initiative must fund research on conditions
affecting a variety of populations and build the trust needed to recruit diverse
research participants.
Dr. Sabatello’s talk addressed issues for persons with disabilities raised by
the precision medicine initiative. She began by pointing out that although 22% of
US adults and 13% of US children have disabilities, disability to date has not
received much discussion in the precision medicine initiative.
To the extent that disabilities are genetic in origin, they will be subject to
disability rights criticisms of genetic research. These include genetic essentialism
and the sorry history of eugenics. Some forms of pre-natal testing, preimplantation genetic analysis, or postnatal predictive and diagnostic testing may
reveal discriminatory attitudes such as the devaluation of lives with disabilities or
the presentation of unjustifiably negative prognoses. Disability rights critics point
to the wide variety of disability and to how the geneticization of impairment may
direct attention and budgetary allotments to medical interventions rather than to
the social and environmental factors that cause or contribute to disability.
Precision medicine has the promise to be attuned to the social model of
disability—how social factors contribute to the impact of disabilities on peoples’
lives—but only if it is constructed to take these factors into account.
Despite the universality of disability, moreover, people with disabilities
continue to experience significant health disparities and disparities in access to
care. There are high rates of co-morbidity that are not well understood, such as
increased risks of epilepsy and Parkinson’s disease among people with
intellectual disabilities, and variant cancer rates among people with
schizophrenia. Physical barriers such as inaccessible clinic design or diagnostic
equipment remain problems. People with disabilities are less likely to participate
in clinical trials. They are also less likely to have private health insurance and
instead to be dependent on Medicaid or Medicare for payment for their care—or
to forego health care instead.
Dr. Sabatello then emphasized the importance of making information about
the precision medicine initiative available to people with disabilities. Accessible
information about participation, such as publicity in Braille or in plain language, is
critical. So is reconsideration of informed consent requirements and processes,
so as not to exclude populations of people with disabilities who might not be able
to sign or understand standard consent forms. Inclusion of people with
psychiatric disabilities may also be an issue from the perspective of informed
consent. Another concern will be how to deal with how people change and
acquire disability over the long course of the precision medicine initiative. It will
be important to consider information and consent as the initiative develops, so
that people are not improperly dropped from the cohort or included when they
would choose not to continue.
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In sum, the precision medicine initiative will require continued attention to
issues of justice, from its beginnings in the questions asked and populations
enrolled, to its endpoints in research discoveries and their translation into
improvements in patient care and public health. These are not static questions
or answers, but will change and develop over time.
4. The Economics of Precision Medicine
a. Patenting And Precision Medicine
Patents have traditionally given the developers of diagnostic and
therapeutic products a period of exclusivity (20 years in the United States and
most other countries) during which to use those products free from market
competition. On one hand, the exclusivity afforded by patent protection enables
inventors to charge rates for their products that offset the significant costs of
product development and regulatory approval (estimated to be in excess of one
billion dollars for a typical pharmaceutical product). On the other hand, the
pharmaceutical industry has been criticized for charging excessive rates that
make life-saving drugs unaffordable to many, both in the U.S. and abroad
(particularly in the developing world). In general, critics of the patent system have
alleged that the issuance of too many patents in areas of biomedical research
can impede research and scientific progress.23
The development of precision medicine therapies has complicated the
patent landscape, with recent Supreme Court decisions casting doubt on the
degree to which such innovations are eligible for patent protection at all. This
panel explored a range of issues relating to the patentability of precision
medicine techniques, the potential impact of recent judicial decisions on
protection offered by the patent system, the effect of patents on biomedical
research at academic institutions and elsewhere, and policy and public health
considerations surrounding all of these issues.
Jorge Contreras introduced this session with an overview of the statutory
and judicial state of the law surrounding patent eligibility in the United States.
Section 101 of the U.S. Patent Act provides that “Whoever invents or discovers
any new and useful process, machine, manufacture, or composition of matter …
may obtain a patent therefor.”24 While this definition can be applied in a relatively
straightforward manner to inventions involving new mechanical devices, serious
questions of patent eligibility arise when an inventor seeks to claim something
derived from the natural world (a so-called “product of nature”), or something that
is in essence an abstract idea or mental process. Traditionally, courts have held

Mark A. Heller and Rebecca S. Eisenberg, Can patents deter innovation? The anticommons in
biomedical research. 280 Science 698 (1998).
24
35 U.S.C. Sec. 101.
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that neither products of nature, abstract ideas nor mental processes are eligible
for patent protection.
These patentability exclusions have recently been put to the test in the
context of biomedical innovation. Beginning with the seminal case Diamond v.
Chakrabarty in 1980,25 the U.S. Supreme Court recognized the patentability of
man-made biological organisms (in this case, a bacterium customized to break
down crude oil). Based on the Chakrabarty decision, the U.S. Patent and
Trademark office (PTO) began to allow patents on biological entities. This
practice became particularly controversial in the area of human DNA. Beginning
in the early 1990s, researchers began to seek patent protection for newlydiscovered DNA sequences. Among the most controversial of these were patents
obtained by Myriad Genetics and the University of Utah on the BRCA1 and
BRCA2 genes, as well as certain mutations to those genes that indicated
substantially elevated risk for breast and ovarian cancer. The BRCA patents
were challenged in a 2009 lawsuit, which alleged that they covered products of
nature that were ineligible for patent protection.26 In 2013, the Supreme Court
invalidated most of the challenged patent claims, holding that human DNA, even
if isolated and purified in the laboratory, constituted a product of nature that was
not patentable subject matter.27
Even more relevant for precision medicine are individualized treatment
regimens based on patient physiology and responses. In 2006, three justices of
the Supreme Court hinted that they were skeptical of patents claiming such
diagnostic methods.28 However, it was not until 2012, in Mayo v. Prometheus,29
that the Court squarely considered the patentability of a personalized medical
treatment. In Mayo, the challenged patent claimed a method of determining the
optimal dosage of thiopurine (a drug for an immune-mediated gastrointestinal
disorder) by monitoring the level of 6-thioguanine (a metabolite of thiopurine) in a
patient’s blood after administration of the drug. If metabolite levels were below a
certain level, the thiopurine dosage should be increased, and vice versa. The
Court, in holding that the claimed subject matter was not patent eligible,
reasoned that the relationship between metabolite levels and drug efficacy is a
“law of nature”, and that a patent should not be granted unless the inventor adds
“additional features” beyond that basic natural law. Moreover, the physician’s
447 U.S. 303, 317-18 (1980).
For a detailed account of the BRCA litigation see, e.g., Jorge L. Contreras, Narratives of Gene
Patenting, 43 FLA. ST. L. REV. 1133 (2016), and Sandra S. Park, Gene Patents and the Public
Interest: Litigating Association for Molecular Pathology v. Myriad Genetics and Lessons Moving
Forward, 15 N.C. J.L. & TECH. 519 (2014).
27 133 S. Ct. 2107 (2013). The Court also held, however, that man-made DNA segments (e.g.,
cDNA), even if replicating the sequence of naturally-occurring DNA, were eligible for patent
protection.
28 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. 548 U.S. 124 (2006) (dissent to denial of
certiorari).
29 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012).
25
26
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observation of metabolite levels in the blood and decision to alter the patient’s
thiopurine dosage on that basis, is simply a mental process. Thus, because the
claimed invention simply relied on an observation of a natural relationship and a
corresponding alteration of the patient’s drug dosage, the patent was found to be
invalid.
Bernard Chao, in a talk entitled “Measuring the Mayo Effect,” began by
noting many of the dire predictions made by commentators following the Mayo
decision. These commentators predicted that in the wake of Mayo, many
personalized medicine technologies would no longer be patentable, thereby
causing serious problems for the medical diagnostics industry and potentially
reducing innovation in this field. 30 To test these predictions empirically, Prof.
Chao and collaborators measured the number of precision medicine patent
applications rejected by the PTO from 2006 through 2016, a ten-year period
spanning the issuance of the Mayo decision. Based on a sample of 10% of the
total set of patent applications filed in the relevant technology class, they found
that PTO rejection of applications based on Section 101 patent eligibility grounds
increased dramatically, from 15.9% prior to the Mayo case to 86.4% after
Mayo. 31 He also described a subsequent study in which the investigators
compared Section 101 patent eligibility rejections across ten different technology
classes. They found the highest rate of such rejections in the class pertaining to
precision medicine. Further studies are being planned to obtain more detailed
data on these rejections and their impact.
Colleen Chien also addressed the impact of Mayo and a related 2010
patent eligibility case, Bilski,32 in a talk discussing work conducted with Arti Rai of
Duke University. Professors Chien and Rai sought to understand the impact of
patentability limitations on innovation in the medical diagnostics industry. They
found that in the area of biomarker-based diagnostics, patent application filings
(which are viewed as proxies for innovation) dipped immediately after the Mayo
case, but have recovered since then, suggesting that firms have developed
effective strategies for overcoming Section 101 eligibility rejections in this field.
Likewise, they found that Mayo had no significant impact on either the size of
firms patenting in the area of diagnostics or the number of commercial
transactions conducted in the diagnostics industry (which increased sharply after
2012). However, based on measurable increases in the word length of patent
claims, they hypothesize that the scope of patent protection in the diagnostics
30

See, e.g., Arti Rai, Biomedical Patents at the Supreme Court: A Path Forward , 66 Stan. L.
Rev. Online 111 (2013), Christopher Holman Mayo, Myriad, and the Future of Innovation in
Molecular Diagnostics and Personalized Medicine, 15 N.C. J. L. & TECH. 639, 677 (2014),
Rebecca S. Eisenberg, Diagnostics Need Not Apply, 21 B.U. J. SCI. & TECH. L. 256, 285 (2015).
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Bernard Chao and Amy Mapes, An Early Look at Mayo’s Impact on Personalized Medicine
Patenting, Patently-O blog (April 4 2016), http://patentlyo.com/lawjournal/2016/04/personalizedmedicine-patenting.html. See also Heidi Ledford, US Personalized Medicine Industry Takes Hit
from Supreme Court, 536 Nature 382 (2016).
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Bilski v. Kappos, 561 U.S. 593 (2010).

Precision Medicine II

Page 21

field has narrowed since Mayo, as firms have been required to add additional
limitations to their patent claims in order to overcome Section 101 rejections.
They conclude that, notwithstanding many predictions, innovation in the field of
biomarker-based diagnostics has increased, not declined, since Mayo.
Next, Kshitij Kumar Singh offered an international perspective on precision
medicine patenting with a particular focus on India. He first noted a number of
challenges facing India and other developing countries in the area of healthcare,
notably the affordability and accessibility of advanced medical technologies and
treatments, the difficulties of a large and disorganized health and insurance
sector, and a fragmented research landscape. Given these challenges, coupled
with the dominance of foreign firms in the biopharmaceutical industry, policy
makers in India have become wary of intellectual property protection for
biomedical products. Accordingly, as permitted under the TRIPS Agreement,33
the Indian Patent Act prohibits the patenting of “any process for the medicinal,
surgical, curative, prophylactic [diagnostic, therapeutic] or other treatment of
human beings or any process for a similar treatment of animals to render them
free of disease or to increase their economic value or that of their products.”34
However, he also noted that if an invention includes a novel biomarker or
detection method, there may be ways to pursue patent protection. The impact of
such policies on both foreign firms seeking to enter markets in developing
countries, as well as local innovators in those countries, will be important as
policy makers in developing countries continue to refine their local legal
structures to address emerging technologies in the field of precision medicine.35
In the final presentation of this session, Shubha Ghosh discussed the
current policy landscape pertaining to precision medicine, big data and
intellectual property.36 He observed the increasing emphasis on data extraction
and analysis in the biomedical field, which has been coupled with increasing
patenting in this area. He also examined current administration proposals in
areas including Medicaid/Medicare reform and competition law enforcement and
their potential impact on innovation. He then questioned whether incremental
innovation in U.S. precision medicine will be likely in view of the current policy
and political landscape. Ultimately, he concluded, incentives must be available to
encourage innovation, though these incentives may arise from mechanisms other
than patent law.

33

Article 27.3 (a) gives Member Nations of WTO an option to exclude from patentability
"diagnostic, therapeutic and surgical methods for the treatment of humans or animals
34
Indian Patents Act 1970, amended 2005, Sec. 3(i).
35
See, generally, Kshitij Kumar Singh, Biotechnology and Intellectual Property Rights: Legal and
Social Implications (Springer, 2015).
36
See, generally, Shubha Ghosh, Identity, Invention, and the Culture of Personalized Medicine
Patenting (Cambridge Univ. Press, 2013).
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b. Providers, Payers, and Laboratory Testing
In the final session, Dr. Diana Brixner introduced the audience to the
complex world of reimbursement from a payer perspective. There has been
explosive growth in the number of specialty, frequently expensive drugs, which is
differentiated from those—generally small molecules or pills—used in primary
care for complex chronic disorders. The overall proportion of the pharmaceutical
budget devoted to specialty drugs has similarly increased, posing a growing
dilemma for payers on how to pay for these drugs through insurance without
increasing member premiums. One tool for assessment of these new, expensive
drugs is to balance the differential benefit against the differential cost.
Different professional groups are attempting to grapple with measuring
“value” of therapeutic interventions being used by practitioners. NCCN (National
Comprehensive Cancer Network) and ASCO (American Society of Clinical
Oncology) are two major examples for oncology. NCCN provides a grade of 1
(weak) to 5 (strong) for available clinical evidence on key parameters of efficacy;
safety; availability of comparative data; consistency of data; and affordability,
related to drug-acquisition cost. ASCO utilizes a value framework in evaluating
the clinical benefit of cancer treatments against their costs and toxicity.
Conceptually, there is an attempt to compare the net benefits (improvement in
survival vs. toxicity of therapy) of two comparative regimens to identify the
intervention of greater value. Another society—ICER (Institute for Clinical and
Economic Review, not to be confused with the same acronym which denotes
incremental cost-effectiveness ratio)—seeks to attain sustainable high-value care
for all patients. Its value framework evaluates long-term value-for-money
assessments based on incremental and comparative cost-effectiveness, and
short-term affordability as assessed by budget impact. As information on value
become more available, innovative contracting approaches are evolving. For
example payers may be reimbursed by the drug manufacturer if specific clinical
outcomes are not achieved from the therapeutic intervention, called “outcomesbased contracting”. For drug interventions that require a significant initial
payment, for example Solvadi in treating and potentially curing hepatitis C, the
initial cost can be shared by the initial and future payers. Personalized medicine
will play a larger role in defining the health plan population that will receive the
greatest benefit from these new therapies.
Payers are also assessing different ways of contracting with health care
providers. These include contracting and reimbursing for management of a
disease rather for individual drugs
Dr. Christopher Corless outlined the promise that a deeper molecular
understanding of disease—for example the new taxonomy of non-small cell lung
cancer—and targeted therapies such as ALK-directed medicines are providing to
stricken patients. He then delineated the health care provider dilemma: precision
medicine and targeted therapies require accurate diagnostics, but development
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and regulatory approval of both the therapy and the diagnostic test are commonly
asynchronous, and reimbursement approval is haphazard and insufficient to
compensate for the major laboratory investments required to handle biological
samples and analyses. Hence cumbersome barriers frequently confront both
patient and provider.
A more logical manner of reimbursement in oncology is an urgent need.
The burgeoning field of immuno-oncology will require laboratories to evaluate
both tumor samples and the patient’s own immune system. Furthermore,
following cancer patients over time ideally requires both extensive initial
evaluation of the tumor and its microenvironment but also metastatic lesions or
chemotherapy-unresponsive tumors.
Finally, advances in other “–omics”
technologies and the increasing data load requires great technical expertise and
is costly.
Dr. Craig Nichols concluded with a historical perspective on advances in
precision medicine. He cautioned the audience to recognize the potential
limitations of new therapeutic interventions, the duration of time required for
incorporation of medical advances into clinical practice, and importance of the
breadth of factors (medical, genetics, socio-economic, environmental) that impact
an individual’s health and well-being. Finally, he emphasized the importance of
the cancer care process which must include careful consideration of patient’s
wishes.
Conclusion
Precision medicine is being developed within a complex landscape of
public policy, science, economics, law, and regulation. In these and other policy
areas, the goal of developing individually-tailored therapies poses novel
challenges for health care research, delivery and policy. In this symposium, a
range of experts in genetics, medicine, bioinformatics, intellectual property,
health economics and bioethics identified and discussed many of the
pressing questions raised by the development and practice of precision
medicine. These and other issues will need to be taken into account as precision
medicine moves ahead and becomes the standard of medical practice and care
in the United States and around the world.
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Appendix
FRONTIERS IN PRECISION MEDICINE II:
CANCER, BIG DATA AND THE PUBLIC
December 1-2, 2016
University of Utah S.J. Quinney College of Law

Agenda
Thursday, December 1, 2016
1. Tackling Cancer with Precision Data
a. The Science of Precision Oncology
Moderator: Ana Maria Lopez, M.D., M.P.H., F.A.C.P., Professor of Internal
Medicine; Associate Vice President for Health Equity and Inclusion; and
Director of Cancer Health Equity at Huntsman Cancer Institute, University of
Utah
Kathleen Cooney, M.D., F.A.C.P., Professor and Chair of Internal Medicine,
University of Utah
Scott Tomlins, M.D., Assistant Professor of Genitourinary Pathology, University
of Michigan
b. The Challenges of Big Data
Moderator: Kensaku Kawamoto, M.H.S., M.D., Ph.D., University of Utah
Samir Courdy, M.B.A., Huntsman Cancer Institute
Rakesh Nagarajan, M.D., Ph.D., Founder and Chief Information Officer at
PierianDx and Adjunct Associate Professor of Pathology and Immunology,
Washington University in St. Louis
David Nix, Ph.D., Co-Director of Bioinformatics Shared Resource, Huntsman
Cancer Institute
c. Precision Prevention
Moderator: Cornelia Ulrich, M.S., Ph.D., Senior Director of Population Sciences
at Huntsman Cancer Institute and Division Chief of Population Health Sciences,
University of Utah
Ulrike Peters, M.P.H., Ph.D., M.S., Research Professor of Epidemiology,
University of Washington, Full Member at Fred Hutchinson Cancer Research
Center
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Marc Lenburg, Ph.D., Professor of Medicine in the Division of Computational
Biomedicine, Boston University
2. Keynote Address
Catalyzing Translational Innovation
Christopher Austin, M.D., Director, National Center for Advancing Translational
Sciences (NCATS)
3. The Public and Precision Medicine
a. Recruiting Large Research Cohorts
Moderator: James Tabery, Ph.D., Professor of History and Philosophy of
Science, University of Utah
Laurence Meyer, M.D., Ph.D., Veterans Administration Medical Center
Catherine Schaefer, Ph.D., Kaiser Permanente Division of Research
b. Engaging the Public in the Program
Moderator: Jeffrey Botkin, M.D., M.P.H., Professor of Pediatrics, University of
Utah
Angela Fagerlin, Ph.D., Professor of Population Health Sciences, University of
Utah
Kimberly Kaphingst, Sc.D., Health Communication Researcher, University of
Utah
c. The Ethics of Access and Precision Medicine
Moderator: Leslie Francis, Ph.D., J.D., Professor of Law and Philosophy,
University of Utah
Jessica Roberts, J.D., Director of the Health Law and Policy Institute, University
of Houston Law Center
Maya Sabatello, Ph.D., Columbia University College of Physicians and
Surgeons
Friday, December 2, 2016
4. Economics and Precision Medicine
a. Patenting Precision Medicine
Moderator: Jorge L. Contreras, J.D., Professor of Law, University of Utah
Bernard Chao, J.D., Associate Professor of Law, University of Denver
Colleen Chien, J.D., Associate Professor of Law, Santa Clara University
Shubha Ghosh, J.D., Ph.D., Director of the Technology Commercialization Law
Center, Professor of Law, Syracuse University
Kshitj Kumar Singh, Ph.D., Assistant Professor of Law, Amity Institute of
Advanced Legal Studies
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b. Providers, Payer, and Laboratory Testing
Moderator: Allie Grossmann, M.D., Ph.D., Assistant Professor of Pathology,
University of Utah
Diana Brixner, R.Ph., Ph.D., Professor in the Department of Pharmacology,
University of Utah
Christopher Corless, M.D., Ph.D., Professor of Pathology, Oregon Health &
Science University
Craig Nichols, M.D., Intermountain Healthcare
Concluding Remarks
Willard Dere, M.D., Professor of Internal Medicine, University of Utah
Jorge L. Contreras, J.D., Professor of Law, University of Utah

